memantine has been researched along with oxybutynin in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Choi, SH; Han, HJ; Kim, EJ; Lee, JH; Na, DL; Park, KW; Shim, YS | 1 |
| Cho, SJ; Choi, MS; Choi, SH; Han, HJ; Heo, JH; Kim, BC; Kim, KK; Lee, JY; Na, HR; Park, HY; Park, KW; Ryu, SH; Shin, JH; Yi, HA; Yoon, SJ | 1 |
| Cho, SJ; Choi, SH; Han, HJ; Kim, JE; Kim, SG; Kwon, JC; Moon, SY; Park, JM; Park, KC; Park, KH; Park, KW; Seo, SW | 1 |
| Farlow, MR; Grossberg, GT; Meng, X; Velting, DM | 1 |
| Bae, CS; Cho, IH; Choi, BM; Kim, EJ; Kim, SH; Lee, SH; Noh, GJ; Noh, YH; Park, WD | 1 |
| Deardorff, WJ; Grossberg, GT | 1 |
| Fujioka, S; Futagami, K; Kamimura, H; Ouma, S; Shibaguchi, H; Terasawa, M; Tsuboi, Y; Yasutaka, Y | 1 |
| Arfi, S; Bhatta, RS; Mishra, PR; Mittapelly, N; Pandey, G; Tulsankar, SL | 1 |
2 review(s) available for memantine and oxybutynin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Humans; Indans; Memantine; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Transdermal Patch | 2016 |
4 trial(s) available for memantine and oxybutynin
| Article | Year |
|---|---|
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Male; Memantine; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2011 |
Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Cholinesterase Inhibitors; Drug Therapy, Combination; Female; Genotype; Humans; Male; Memantine; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine; Transdermal Patch | 2012 |
Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.
Topics: Aged; Alleles; Alzheimer Disease; Apolipoprotein E4; Butyrylcholinesterase; Female; Genetic Testing; Genotype; Humans; Male; Memantine; Middle Aged; Neuroprotective Agents; Odds Ratio; Rivastigmine; Transdermal Patch | 2015 |
Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Case-Control Studies; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Memantine; Neuroprotective Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Quality of Life; Rivastigmine; Transdermal Patch; Treatment Outcome | 2015 |
5 other study(ies) available for memantine and oxybutynin
| Article | Year |
|---|---|
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats.
Topics: Administration, Cutaneous; Administration, Intravenous; Administration, Oral; Alzheimer Disease; Animals; Area Under Curve; Biological Availability; Disease Models, Animal; Dose-Response Relationship, Drug; Half-Life; Memantine; Nootropic Agents; Rats; Transdermal Patch | 2016 |
Influence of Memantine on Continuous Treatment with Rivastigmine Patches-Retrospective Study Using the Logistic Regression Analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Memantine; Middle Aged; Patient Compliance; Retrospective Studies; Rivastigmine; Transdermal Patch | 2017 |
In Depth Analysis of Pressure-Sensitive Adhesive Patch-Assisted Delivery of Memantine and Donepezil Using Physiologically Based Pharmacokinetic Modeling and in Vitro/in Vivo Correlations.
Topics: Administration, Cutaneous; Alzheimer Disease; Animals; Biological Availability; Donepezil; Drug Delivery Systems; Drug Liberation; Excipients; Memantine; Models, Animal; Models, Biological; Nootropic Agents; Pressure; Rats; Rats, Sprague-Dawley; Skin; Skin Absorption; Transdermal Patch | 2018 |